Skip to content
Free shipping and returns
  • About SUDOSCAN®
  • Our Company
  • Medical Articles
  • Approved Cleaning Products
  • Media & Events
  • Contact Us
  • SUDOSCAN® Shop
  • Log in
  • YouTube
  • LinkedIn
Cart
Subtotal
$0.00
Shipping, taxes, and discount codes calculated at checkout.
Your cart is currently empty.
Refundable Security Deposit for Sudoscan Refundable Security Deposit for Sudoscan Sudoscan Logo white Sudoscan Logo white
  • About SUDOSCAN®
  • Our Company
  • Medical Articles
  • Approved Cleaning Products
  • Media & Events
  • Contact Us
  • SUDOSCAN® Shop
account Log in icon-bag-minimalCart
Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Home / Media & Events / SUDOSCAN® used in conjunction with other diagnostic tests to confirm small fiber neuropathy
Neurological diseases · Scientific publications · Feb 18, 2023

SUDOSCAN® used in conjunction with other diagnostic tests to confirm small fiber neuropathy

Graph of other diagnostic tests used with Sudoscan to confirm small fiber neuropathy

Combining SUDOSCAN with Other Diagnostic Tests to Confirm Small Fiber Neuropath

 

V. Fabry, A. Gerdelat, B. Acket, P. Cintas, V. Rousseau, E. Uro-Coste, S. M. Evrard and A. Pavy-Le Traon.
Article title: “Which Method for Diagnosing Small Fiber Neuropathy?”
Front. Neurol., 05 May 2020.

In a recent study conducted at Toulouse University Hospital, France, Vincent FABRY et al outlines the benefits of combining different diagnosis methods of Small Fiber Neuropathy (SFN) including SUDOSCAN measurement.

The diagnostic value of 6 methods evaluating small sensory and autonomic nerve fibers was determined: skin biopsy, Quantitative Sensory Testing (QST), quantitative sweat measurement system (Q-Sweat), Laser Evoked Potentials (LEP), Electrochemical Skin Conductance (ESC) measurement of SUDOSCAN and Autonomic CardioVascular Tests (ACVT) to evaluate the most relevant diagnostic strategy.

This single center retrospective study was conducted on 245 patients tested for symptoms compatible with SFN between 2013 and 2016 (see Figure 1 for possible etiologies).

The specificity (Sp) and sensitivity (Se) of each test were calculated based on the final diagnosis and the best diagnostic strategy. The final diagnosis (“Definite SFN,” “Possible SFN” or “No SFN”) was combined to clinical data and anomalies in at least 2 of the 6 tests as diagnostic criteria for SFN.

Diagnosis performances of SUDOSCAN were Sp of 89 % and Se of 60 % and the only significant inter-test correlation was between skin biopsy and ESC.
It should be underlined that Autonomic Cardiovascular Tests (ACVT) were not relevant.

The best combination of tests to diagnose SFN comprises skin biopsy, LEP, ESC, and QST that generates a PPV (Positive Predictive Value) of 90%, specificity of 88%, sensitivity of 92% and a NPV (Positive Predictive Value) of 91% (see Table 1).

These results demonstrated the utility of SUDOSCAN combined with other diagnosis tests to confirm SFN within a suspected population with SFN symptoms.

Figure 1

Prevalence of possible cause in patients with definite Small Fiber Neuropathy for whom aetiological investigations were documented.

Prevalence of possible cause in patients with definite Small Fiber Neuropathy for whom aetiological investigations were documented.

Table 1

Comparison of different diagnostic strategies for small fiber neuropathy.

Comparison of different diagnostic strategies for small fiber neuropathy.

QST, Quantitative Sensory Testing; ESC, Electrochemical Skin Conductance; LEP, Laser Evoked Potentials; PPV, Positive Predictive Value; NPV, Negative Predictive Value.

Share Share on Facebook Share Tweet on X Pin it Pin on Pinterest

icon-left-arrow Back to Media & Events
Invalid password
Enter
Sudoscan Logo

SUDOSCAN® is a privately-owned French medical device company.

Created in June 2005, SUDOSCAN is located in San Diego, CA, USA; the company's corporate headquarters are in Paris, France. We service all of the North and South America, The Middle East, Europe and Asia.

  • YouTube
  • LinkedIn

Sudoscan

  • About SUDOSCAN®
  • Our Company
  • Medical Articles
  • Approved Cleaning Products
  • Media & Events
  • Contact Us
  • SUDOSCAN® Shop

Shop SUDOSCAN

  • Login
  • Create account
  • SUDOSCAN® Shop

Resources

  • For Physicians
  • Reimbursement Regulatory
  • Approved Cleaning Products
  • For Patients
  • SUDOSCAN® Videos
  • SUDOSCAN® Image Gallery
  • SUDOSCAN® Articles

CONTACT INFO:

US TERRITORIES:
SUDOSCAN Inc.
8525 Gibbs Dr. Suite 304
San Diego, CA 92123

Phone: +1 858 450 2800

INTERNATIONAL:
Impeto Medical
2 Rue Maurice Hartmann,
92130 Issy-les-Moulineaux,
France

Phone: +33 (0)7 87 20 32 03
Website: www.sudoscan.com

Promotional Communication. The medical devices SUDOSCAN® is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 05/10/2023

  • American Express
  • Diners Club
  • Discover
  • Mastercard
  • Visa
© 2025 SUDOSCAN USA | Autonomic & Sudomotor Testing Device Powered by Shopify
Confirm Small Fiber Neuropathy with SUDOSCAN®